{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:54:50Z","timestamp":1768031690272,"version":"3.49.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome (MERS)\u2013associated coronavirus. Here, we report that cross-reactive monkeypox virus neutralizing antibodies were detectable in only a single study participant after the first dose of MVA-MERS-S vaccine, in 3 of 10 after the second dose, and in 10 of 10 after the third dose.<\/jats:p>","DOI":"10.1093\/infdis\/jiad052","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T19:10:07Z","timestamp":1677697807000},"page":"586-590","source":"Crossref","is-referenced-by-count":12,"title":["Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome\u2013Coronavirus Spike Protein"],"prefix":"10.1093","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3774-8165","authenticated-orcid":false,"given":"Matthijs P","family":"Raadsen","sequence":"first","affiliation":[{"name":"Department of Viroscience, Erasmus MC , Rotterdam , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Dahlke","sequence":"additional","affiliation":[{"name":"University Medical Center Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD) , Hamburg , Germany"},{"name":"Department for Clinical Immunology of Infectious Diseases, Bernhard-Nocht-Institute for Tropical Medicine , Hamburg , Germany"},{"name":"German Center for Infection Research, Partner site Hamburg-L\u00fcbeck-Borstel-Riems , Hamburg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anahita","family":"Fathi","sequence":"additional","affiliation":[{"name":"University Medical Center Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD) , Hamburg , Germany"},{"name":"Department for Clinical Immunology of Infectious Diseases, Bernhard-Nocht-Institute for Tropical Medicine , Hamburg , Germany"},{"name":"German Center for Infection Research, Partner site Hamburg-L\u00fcbeck-Borstel-Riems , Hamburg , Germany"},{"name":"First Department of Medicine, Division of Infectious Diseases, University Medical Center Hamburg-Eppendorf , Hamburg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart M","family":"Lamers","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus MC , Rotterdam , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"van den Doel","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus MC , Rotterdam , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca M","family":"Zaeck","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus MC , Rotterdam , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin E","family":"van Royen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Erasmus MC , Rotterdam , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erwin","family":"de Bruin","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus MC , Rotterdam , the Netherlands"},{"name":"Division of Pathology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University , Utrecht , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reina","family":"Sikkema","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus MC , Rotterdam , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5204-2312","authenticated-orcid":false,"given":"Marion","family":"Koopmans","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus MC , Rotterdam , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric C M","family":"van Gorp","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus MC , Rotterdam , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"Sutter","sequence":"additional","affiliation":[{"name":"Division of Virology, LMU University of Munich, Institute for Infectious Diseases and Zoonoses , Munich , Germany"},{"name":"German Center for Infection Research, Partner Site Munich , Munich , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rory D","family":"de Vries","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus MC , Rotterdam , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marylyn M","family":"Addo","sequence":"additional","affiliation":[{"name":"University Medical Center Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD) , Hamburg , Germany"},{"name":"Department for Clinical Immunology of Infectious Diseases, Bernhard-Nocht-Institute for Tropical Medicine , Hamburg , Germany"},{"name":"German Center for Infection Research, Partner site Hamburg-L\u00fcbeck-Borstel-Riems , Hamburg , Germany"},{"name":"First Department of Medicine, Division of Infectious Diseases, University Medical Center Hamburg-Eppendorf , Hamburg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6221-2015","authenticated-orcid":false,"given":"Bart L","family":"Haagmans","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus MC , Rotterdam , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"2023083107425957400_jiad052-B1","first-page":"633","article-title":"Human infection with monkeypox virus: laboratory investigation of six cases in West Africa","volume":"46","author":"Lourie","year":"1972","journal-title":"Bull World Health Organ"},{"key":"2023083107425957400_jiad052-B2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/infdis\/jis753","article-title":"Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects","volume":"207","author":"Greenberg","year":"2013","journal-title":"J Infect Dis"},{"key":"2023083107425957400_jiad052-B3","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1817307","article-title":"Phase 3 efficacy trial of modified vaccinia Ankara as a vaccine against smallpox","volume":"381","author":"Pittman","year":"2019","journal-title":"N Engl J Med"},{"key":"2023083107425957400_jiad052-B4"},{"key":"2023083107425957400_jiad052-B5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","article-title":"Modified vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development","volume":"97","author":"Volz","year":"2017","journal-title":"Adv Virus Res"},{"key":"2023083107425957400_jiad052-B6","year":"2017"},{"key":"2023083107425957400_jiad052-B7","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1473-3099(20)30248-6","article-title":"Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial","volume":"20","author":"Koch","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2023083107425957400_jiad052-B8","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1038\/s41467-022-31557-0","article-title":"Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome","volume":"13","author":"Fathi","year":"2022","journal-title":"Nat Commun"},{"key":"2023083107425957400_jiad052-B9","doi-asserted-by":"crossref","first-page":"100685","DOI":"10.1016\/j.xcrm.2022.100685","article-title":"Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine","volume":"3","author":"Weskamm","year":"2022","journal-title":"Cell Rep Med"},{"key":"2023083107425957400_jiad052-B10","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-022-02090-w","article-title":"Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals","volume":"29","author":"Zaeck","year":"2022","journal-title":"Nat Med"},{"key":"2023083107425957400_jiad052-B11","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150613","article-title":"Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19","volume":"131","author":"Aguilar-Bretones","year":"2021","journal-title":"J Clin Invest"},{"key":"2023083107425957400_jiad052-B12","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1128\/CVI.00056-12","article-title":"Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines","volume":"19","author":"Hughes","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"2023083107425957400_jiad052-B13","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1473-3099(14)70963-6","article-title":"Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1\/2a clinical trial","volume":"14","author":"Kreijtz","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2023083107425957400_jiad052-B14","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.1016\/j.vaccine.2007.10.017","article-title":"Clinical and immunologic responses to multiple doses of IMVAMUNE (modified vaccinia Ankara) followed by Dryvax challenge","volume":"25","author":"Frey","year":"2007","journal-title":"Vaccine"},{"key":"2023083107425957400_jiad052-B15","article-title":"Vaccine effectiveness of modified vaccinia Ankara in human monkeypox","author":"Arbel","journal-title":"Research Square [Preprint: not peer reviewed]."}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad052\/49549630\/jiad052.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/5\/586\/51312752\/jiad052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/5\/586\/51312752\/jiad052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T07:43:50Z","timestamp":1693467830000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/228\/5\/586\/7060631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3,1]]},"published-print":{"date-parts":[[2023,8,31]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad052","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,3,1]]}}}